T-CURX to acquire Pantherna to advance in vivo CAR-T therapies
Summary
T-CURX has agreed to acquire Pantherna Therapeutics to speed up its work in in vivo CAR-T therapies. The deal is meant to expand the company’s reach beyond oncology and support broader therapeutic applications. This is a strategic M&A move within the biotech and cell therapy space. The announcement does not include financial terms or a closing timeline in the available text.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected